Share this post on:

product name JNJ-26854165 (Serdemetan)


Description: JNJ-26854165, also named as Serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral Human Double Minute-2 (HDM-2) ubiquitin ligase antagonist. It can increase the level of HDM-2 client proteins, such as p53, by inhibiting the association of HDM-2-client protein complex with the proteosome. It demonstrated potent anti-proliferative and apoptosis-inducing activity of JNJ-26854165 in a broad range of p53 wild type and mutant tumor models. 

Reference: Pediatr Blood Cancer. 2012 Aug;59(2):329-32.



Molecular Weight (MW)

328.41
Formula

C21H20N4
CAS No.

881202-45-5
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 66 mg/mL (200.96 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 2 mg/mL (6.08 mM)
Solubility (In vivo)

1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL

other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19415765

General JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks
Animal model CB17SC scid female mice.
Formulation Dissolved in DMSO and then diluted in water.
Dosages 20 mg/kg
Administration Oral gavage
Reference [1] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

Merimepodib